News

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV vaccine candidate.

Results from a Phase 2b clinical trial provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.

Scientists at St. Jude Children’s Research Hospital improved bispecific chimeric antigen receptor (CAR) T–cell immunotherapies for acute myeloid leukemia (AML), corroborated by computational analysis.

A study by University of Pennsylvania researchers shows that secondary cancer development is rare after CAR T-cell therapy and that many patients have achieved long-lasting remission.

An initial trial suggests a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome resulting from Covid-19.

Current immunotherapies work only against cancers of the blood and bone marrow. T cells engineered by Northwestern and UCSF were able to kill tumors derived from skin, lung and stomach in mice.

Researchers have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness of the breast cancer drug T-DM1 if the cancer cells have developed resistance.

Blood tests could predict outcomes of CAR T-cell therapy, helping to optimize cancer treatments and improve their safety and efficacy.

A new therapeutic for stroke based on University of Georgia research will soon enter clinical trials. The U.S. Food and Drug Administration cleared the new drug to enter a Phase 1b/2a clinical trial.

Results from a Phase 3 clinical trial show that the vaccine is safe and effective for those aged 2–59 regardless of whether they have previously been infected with dengue.